Abzena, an end-to-end integrated CDMO for complex biologics and bioconjugates, and Mabqi, a biotech company focused on the discovery and development of fully human antibodies, announced the formation of a strategic partnership.
Natalia Ustyuzhantseva Shutterstock
Partnership concept.
This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution.
Understanding the challenges of early-stage development, Mabqi and Abzena formed their partnership to offer a solution that enables drug developers to seamlessly bridge from discovery through lead candidate selection into pre-clinical development and beyond. Through this collaboration, customers will benefit from combined scientific and technical support, streamlined workflows, and accelerated development timelines.
The partnership’s combined offerings will leverage Mabqi’s LiteMab Antibody Discovery Studio for hit screening, characterisation, and hit selection by using universal & pH-sensitive libraries to identify top lead candidates, and utilise Abzena’s capabilities for developability, cell line development, process development, and GMP manufacturing. Both organisations have extensive expertise in supporting a broad range of modalities, including monoclonal antibodies (mAbs), mAb fragments, bi- and multi-specifics, and bioconjugates.
Campbell Bunce, CSO at Abzena, said, “Our partnership with Mabqi brings together two science-rich organisations that are focused on advancing antibody innovation through integration. The combination of our capabilities enables us to significantly accelerate our customers’ discovery programs from end-to-end by leveraging data to streamline and de-risk earlier on in development, enabling a faster and more successful path to the clinic.”
"Our strategic partnership with Abzena marks a significant milestone in offering an integrated antibody discovery-through-development solution by combining our complementary scientific expertise and advanced capabilities”, said Sylvain Yon, CEO of Mabqi. “Beyond scientific excellence and innovation, what truly sets this collaboration apart is the exceptional human fit between our teams ensuring smooth cooperation, shared dedication to innovation and customer-focused relationship. Together, we are poised to accelerate the development of differentiated therapeutic antibodies that can make a meaningful impact for patients worldwide."